Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence-Reference-Cited by-同舟云学术

Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence

Published:2021-02-20 Issue:3 Volume:20 Page:243-256
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Niederman Michael S.¹,Folaranmi Temitope²,Buchwald Ulrike K.²^ORCID,Musey Luwy²^ORCID,Cripps Allan W.³,Johnson Kelly D.²

Affiliation:

1. Weill Cornell Medical College, Department of Pulmonary Critical Care Medicine, New York, NY, USA

2. Merck & Co., Inc., Kenilworth, NJ, USA

3. Menzies Health Institute Queensland and School of Medicine, Mucosal Immunology Research Group, Griffith University, Queensland, Australia

Funder

funded

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2021.1880328

Reference86 articles.

1. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

2. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly

3. Pneumococcal pneumonia in adults 60 years or older: Incidence, mortality and prevention

4. A century of pneumococcal vaccination research in humans

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial;Nature Communications;2024-08-04

2. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England;Vaccine;2024-07

3. Vaccines for the Elderly and Vaccination Programs in Europe and the United States;Vaccines;2024-05-22

4. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study;Vaccine;2024-05

5. Pneumococcal serotypes and risk factors in adult community acquired pneumonia 2018–20: a multicentre UK cohort study;The Lancet Regional Health - Europe;2024-02